Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Haemonetics Corporation

Haemonetics Corporation (HAE) Stock Overview

Explore Haemonetics Corporation’s financial performance, market position, analyst ratings, and future outlook.

HAE●NYSE
HealthcareMedical - Instruments & Supplies
$78.78
$1.38(1.78%)
U.S. Market opens in 14h 27m

Haemonetics Corporation (HAE)

Meyka AI Score

Z

Key Financials

Market Cap3.6B
P/E Ratio38.91
EPS (TTM)$4.97
ROE0.11%
Fundamental Analysis

AI Price Forecasts

1 Month$55.68
3 Months$58.53
1 Year Target$59.08

HAE Stock Analysis & Investment Overview (NYSE)

Our AI-powered analysis of Haemonetics Corporation (NYSE: HAE) gives investors deep insight into how the stock performs on the NYSE exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Haemonetics Corporation's NYSE-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of HAE on the NYSE shows an RSI of 62.96, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $59.08 for the NYSE listing.

Key metrics behind Haemonetics Corporation's NYSE-traded stock include a P/E ratio of 38.91 and a market capitalization of 3.6B. Combined with our AI analysis, these give both institutional and retail investors a clear view of HAE on the NYSE.

Price Performance (NYSE: HAE)

1-Day Change
1.85%
5-Day Change
1.90%
1-Month Change
8.18%
3-Month Change
31.54%
6-Month Change
14.55%
Year-to-Date (YTD) Change
-1.65%
1-Year Change
6.15%
3-Year Change
-13.95%
5-Year Change
33.86%
All-Time (Max) Change
1227.66%

Contact Information

https://www.haemonetics.com
781 848 7100
125 Summer Street, Boston, MA, 02110

Company Facts

30,090 Employees
IPO DateMay 10, 1991
CountryUS
Actively Trading

Frequently Asked Questions